Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Recombinant activated factor VII (rFVIIa, NovoSeven) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Drug Design, Development and Therapy |
| Vol/bind | 4 |
| Sider (fra-til) | 107-16 |
| Antal sider | 10 |
| ISSN | 1177-8881 |
| Status | Udgivet - 1 jan. 2010 |
ID: 34110656